Log in
NASDAQ:GLPG

Galapagos Stock Forecast, Price & News

$125.84
+5.06 (+4.19 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$123.44
Now: $125.84
$125.90
50-Day Range
$114.53
MA: $127.03
$148.25
52-Week Range
$112.00
Now: $125.84
$274.03
Volume108,542 shs
Average Volume158,911 shs
Market Capitalization$8.22 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.79
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjögren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Read More
Galapagos logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLPG
CUSIPN/A
Phone321-534-2900
Employees1,003

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.00 billion
Cash Flow$6.27 per share
Book Value$58.75 per share

Profitability

Net Income$167.83 million

Miscellaneous

Market Cap$8.22 billion
Next Earnings Date3/26/2021 (Estimated)
OptionableOptionable
$125.84
+5.06 (+4.19 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GLPG News and Ratings via Email

Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Galapagos (NASDAQ:GLPG) Frequently Asked Questions

How has Galapagos' stock been impacted by Coronavirus (COVID-19)?

Galapagos' stock was trading at $186.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GLPG shares have decreased by 32.4% and is now trading at $125.84.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Galapagos?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galapagos in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Galapagos
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Galapagos?

Wall Street analysts have given Galapagos a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galapagos wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Galapagos' next earnings date?

Galapagos is scheduled to release its next quarterly earnings announcement on Friday, March 26th 2021.
View our earnings forecast for Galapagos
.

What price target have analysts set for GLPG?

16 analysts have issued twelve-month target prices for Galapagos' stock. Their forecasts range from $123.00 to $290.00. On average, they expect Galapagos' stock price to reach $180.15 in the next twelve months. This suggests a possible upside of 43.2% from the stock's current price.
View analysts' price targets for Galapagos
.

Who are some of Galapagos' key competitors?

What other stocks do shareholders of Galapagos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galapagos investors own include Gilead Sciences (GILD), Celyad Oncology (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Biogen (BIIB), Pharming Group (PHGUF), The Trade Desk (TTD) and Collegium Pharmaceutical (COLL).

Who are Galapagos' key executives?

Galapagos' management team includes the following people:
  • Mr. Onno van de Stolpe, Co-Founder, Chairman of the Management Board, MD & CEO (Age 61)
  • Mr. Bart Filius M.B.A., MBA, COO & CFO (Age 50)
  • Dr. Piet Wigerinck, Chief Scientific Officer (Age 56)
  • Dr. Andre Hoekema, Chief Bus. Officer (Age 63)
  • Dr. Walid Abi-Saab, Chief Medical Officer (Age 55)
  • Ms. Elizabeth Goodwin, VP of Investor Relations
  • Ms. Carmen Vroonen, Sr. Director of Communications & Public Affairs
  • John Montana, Managing Director of Argenta
  • Ms. Chantal Tasset, Head of Devel.
  • Ms. Ellen Van Der Aar, Head of Devel.

When did Galapagos IPO?

(GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at a price of $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

What is Galapagos' stock symbol?

Galapagos trades on the NASDAQ under the ticker symbol "GLPG."

Who are Galapagos' major shareholders?

Galapagos' stock is owned by a number of retail and institutional investors. Top institutional investors include Sands Capital Management LLC (3.50%), Federated Hermes Inc. (2.18%), BlackRock Inc. (0.53%), OLD Mission Capital LLC (0.17%), Morgan Stanley (0.08%) and Wells Fargo & Company MN (0.07%).

Which major investors are selling Galapagos stock?

GLPG stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Acadian Asset Management LLC, Envestnet Asset Management Inc., Eqis Capital Management Inc., Peregrine Capital Management LLC, Aperio Group LLC, Sei Investments Co., and Henry James International Management Inc..

Which major investors are buying Galapagos stock?

GLPG stock was purchased by a variety of institutional investors in the last quarter, including OLD Mission Capital LLC, Sands Capital Management LLC, Alpine Woods Capital Investors LLC, Schonfeld Strategic Advisors LLC, Aigen Investment Management LP, Voloridge Investment Management LLC, Avalon Investment & Advisory, and Wells Fargo & Company MN.

How do I buy shares of Galapagos?

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galapagos' stock price today?

One share of GLPG stock can currently be purchased for approximately $125.84.

How big of a company is Galapagos?

Galapagos has a market capitalization of $8.22 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. Galapagos employs 1,003 workers across the globe.

What is Galapagos' official website?

The official website for Galapagos is www.glpg.com.

How can I contact Galapagos?

Galapagos' mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]

This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.